



Colc


DOCKET NO: L0461.70097US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,897,288 B1
Issue Date: May 24, 2005
Patentee: Heidecker et al.
Serial No.: 09/692,401
Confirmation No.: 7318
Filed: October 19, 2000
For: MAGE-A12 ANTIGENIC PEPTIDES AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6th day of June, 2005.


June Watson

Mail Stop Certificate of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
JUN 14 2005
of Correction

Sir:


Transmitted herewith are the following document(s):

- ☒ Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255
- ☒ Certificate of Correction - Form PTO-1050
- ☒ Copy of pertinent page from U.S. Patent No. US 6,794,131 B1
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.


No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Heidecker, et al., Patentee

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70097US00
Date: June 6, 2005
xNDD

JUN 15 2005




DOCKET NO: L0461.70097US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,897,288 B1
Issue Date: May 24, 2005
Patentee: Heidecker et al.
Serial No.: 09/692,401
Confirmation No.: 7318
Filed: October 19, 2000
For: MAGE-A12 ANTIGENIC PEPTIDES AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6th day of June, 2005.


June Watson

Mail Stop Certificate of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Transmitted herewith are the following document(s):

- ☒ Request for Entrance of Certificate of Correction Under 35 U.S.C. §254 & §255
- ☒ Certificate of Correction - Form PTO-1050
- ☒ Copy of pertinent page from U.S. Patent No. US 6,794,131 B1
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned collect at (617) 646-8000, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Heidecker, et al., Patentee

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70097US00
Date: June 6, 2005
xNDD

JUN 15 2005




DOCKET NO: L0461.70097US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,897,288 B1
Issue Date: May 24, 2005
Patentee: Heidecker et al.
Serial No.: 09/692,401
Confirmation No.: 7318
Filed: October 19, 2000
For: MAGE-A12 ANTIGENIC PEPTIDES AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6th day of June, 2005.


June Watson

Mail Stop Certificate of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR ENTRANCE OF CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. §254 and §255


Sir/Madam:

Patentee respectfully requests the correction of an error in the printing of the above-captioned patent. Specifically, claim 4 has a typographical error made by the Patent Office. Please correct as follows: In column 54, line 43, "peptide" should be replaced with --peptide--.

Patentee points out that the correction requested does not involve change in the patent that constitutes new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentee encloses a copy of the issued patent with the error highlighted. Since the error was made by the Patent Office, it is respectfully submitted that no fee is due. However, if the Examiner deems a fee necessary, the fee may be charged to Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

For the reasons stated above, Patentee respectfully requests entrance of the enclosed Certificate of Correction.

Respectfully submitted,
Heidecker, et al., Patentee

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. L0461.70097US00
Date: June 6, 2005
xNDD

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : US 6,897,288 B1

DATED : May 24, 2005

INVENTORS : Heidecker, et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

Claim 4,

In Column 54, line 43, delete "peptidc" and replace with --peptide--.

MAILING ADDRESS OF SENDER:

John R. Van Amsterdam
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211

PATENT NO. US 6,897,288 B1



US 6,897,288 B1

53

54

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 52

ctcctaaggg gcacagtcgc

20

<210> SEQ ID NO 53
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 53

tcagatgcct acaacacact

20

<210> SEQ ID NO 54
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 54

ggaccctaca ggaactcgta

20

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 55

cgttggagggt cagagaacag

20

<210> SEQ ID NO 56
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 56

gccctccact gatcttttagc aa

22

We claim:

1. An isolated MAGE-A12 HLA class I binding peptide consisting of a fragment of the amino acid sequence of SEQ ID NO:2 which binds HLA Cw*07, wherein the fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

2. A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 1 and a pharmaceutically acceptable carrier.

3. A non-hydrolyzable isolated MAGE-A12 HLA class I-binding peptide consisting of a fragment of the amino acid sequence of SEQ ID NO: 2 that binds HLA Cw*07, wherein the fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, wherein said sequence comprises one or more D-amino acid residues.

4. A non-hydrolyzable isolated MAGE-A12 HLA class I-binding peptide consisting of a fragment of the amino acid sequence of SEQ ID NO: 2 that binds HLA Cw*07, wherein the fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, wherein said sequence comprises one or more non-hydrolyzable peptide bonds selected from the group consisting of a -psi[CH₂NH]-reduced amide peptide bond, a -psi[COCH₂]-ketomethylene peptide bond, a -psi

peptide
[CH(CN)NH]-(cyanomethylene)amino peptide bond, a -psi [CH₂CH(OH)]-hydroxyethylene peptide bond, a -psi [CH₂O]-peptide bond, and a -psi[CH₂S]-thiomethylene peptide bond.

5. An isolated MAGE-A12 HLA-C binding peptide consisting of the amino acid sequence of SEQ ID NO:4.

6. A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 5 and a pharmaceutically acceptable carrier.

7. A non-hydrolyzable isolated MAGE-A12 HLA-C binding peptide consisting of the amino acid sequence of SEQ ID NO: 4, wherein said sequence comprises one or more D-amino acid residues.

8. A non-hydrolyzable isolated MAGE-A12 HLA-C binding peptide consisting of the amino acid sequence of SEQ ID NO: 4, wherein said sequence comprises one or more non-hydrolyzable peptide bonds selected from the group consisting of a -psi[CH₂NH]-reduced amide peptide bond, a -psi[COCH₂]-ketomethylene peptide bond, a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, a -psi[CH₂O]-peptide bond, and a -psi[CH₂S]-thiomethylene peptide bond.

9. An isolated MAGE-A12 HLA-C binding peptide consisting of the amino acid sequence of SEQ ID NO:5.

10. A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 9 and a pharmaceutically acceptable carrier.